Diagnostic implications of L1, p16, and Ki-67 proteins and HPV DNA in low-grade cervical intraepithelial neoplasia

International Journal of Gynecological Pathology

Volumn 30, Issue 6, 2011, Pages 597-604

  Gatta, Luisa Benerini ^a   Berenzi, Angiola ^a   Balzarini, Piera ^a   Dessy, Enrico ^a   Angiero, Francesca ^b   Alessandri, Giulio ^c   Gambino, Angela ^d   Grigolato, Piergiovanni ^a   Benetti, Anna ^a  

^a Spedali Civili di Brescia   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

^d NONE

Author keywords

Cervix; CIN1; HPV DNA; L1; p16

Indexed keywords

CAPSID PROTEIN L1; KI 67 ANTIGEN; MOLECULAR MARKER; PROTEIN E6; PROTEIN E7; PROTEIN P16; VIRUS DNA;

ADULT; ARTICLE; CANCER GROWTH; CATALYSIS; COLORIMETRY; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GENOME; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; PATIENT IDENTIFICATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

CAPSID PROTEINS; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; CERVICAL INTRAEPITHELIAL NEOPLASIA; DISEASE PROGRESSION; DNA, VIRAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KI-67 ANTIGEN; NEOPLASM PROTEINS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 80053975516     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e31821ac4fd     Document Type: Article

References (20)

1. Rouzier R. Management of CIN1. J de Gynecol Ostret et Biol de la Reprodution 2008;375:S114-20.
2. Rozendaal L, Walboomers JMM, Van der Linden JC. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer 1996;68:766-9. (Pubitemid 27062038)
3. Schiffman MH, Bauer HM, Hoover RN. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-64. (Pubitemid 23177581)
4. Nindl I, Greinke C, Zahm D, et al. Human papillomavirus distribution in cervical tissues of different morphology as determined by hybrid capture assay and PCR. Int J Gynecol Pathol 1997;16:197-204. (Pubitemid 27282291)
5. Yoshida T, Sano T, Kanuma T, et al. Immunochemical analysis of HPV L1 capsidic protein and p16 protein in liquidbased cytology samples from uterine cervical lesions. Cancer Cytopathol 2008;114:83-8. (Pubitemid 351640786)
6. Hopman AHN, Smedts F, Dgnef W, et al. Transition of highgrade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities. J Pathol 2004;202:23-33. (Pubitemid 38072842)
7. Queiroz C, Silva TC, Alves VAF, et al. P16 expression as a potential prognostic marker in cervical preneoplastic and neoplastic lesions. Pathology 2006;202:77-83. (Pubitemid 43125707)
8. Arafa M, Boniver J, Delvenne P. Detection of HPV-induced cervical (Pre) neoplastic lesions. Apl Immunohistochem Mol Morphol 2008;16:422-23.
9. Tsai HT, Wu CH, Lai HL, et al. Association between quantitative high-risk human papillomavirus DNA load and cervical intraepithelial neoplasm risk. Cancer Epidemiol Biomarkers Prev 2005;14:2544-49.
10. De Marchi Triglia R, Metze K, Zeferino LC, et al. HPV in situ hybridization signal patterns as a marker for cervical intraepithelial neoplasia progression. Gynecol Oncol 2009;112: 114-18.
11. Kruse AJ, Skaland I, Janssen EA, et al. Quantitative molecular parameters to identify low-risk and high-risk early cin lesions: role of markers of proliferative activity and differentiation and Rb Availability. Int J Gynecol Pathol 2004;23:100-109. (Pubitemid 38391768)
12. Evans MF, Mount SL, Beatty BG, et al. Biotinyl-tyramide-based in situ hybridization signal patterns distinguish human papillomavirus type and grade of cervical intraepithelial neoplasia. Mod Pathol 2002;15:1339-47. (Pubitemid 35463003)
13. Nelson W, Moser RP, Gaffey A, et al. Adherence to cervical cancer screening guidelines for U.S. women aged 25-64: data from the 2005 Health Information National Trends survey (HINTS). J Womens Health 2009;18:1759-68.
14. Huang MZ, Li HB, Nie XM, et al. An analysis on the combination expression of HPV L14 capsidic protein and p16ink4a in cervical lesions. Diagn Cytopathol 2009;0:1-6.
15. Kosel S, Burggraf S, Engelhardt W, et al. Increased levels of HPV16 E6*I transcripts in high-grade cervical cytology and histology (CINII+) detected by rapid real-time RT-PCR amplification. Cytopathology 2007;18:290-99. (Pubitemid 47476152)
16. Keating JT, Cviko A, Riethdorf S, et al. Ki-67, cyclin E, and p16INK4 are complementary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 2001;25:884-891. (Pubitemid 32594981)
17. Kalof AN, Evans MF, Simmons-Arnold L, et al. p16INK4A immunoexpression and HPV in situ hybridization signal patterns: potential markers of highgrade cervical intraepithelial neoplasia. Am J Surg Pathol 2005;29:674-9. (Pubitemid 40577879)
18. Negri G, Bellisano G, Zannoni GF, et al. p16 ink4a and HPV L1 immunohistochemistry is helpful for estimating the behaviour of low-grade dysplastic lesions of the cervix uteri. Am J Surg Pathol 2008;32:1715-20.
19. McCluggage WG, Bharucha H, Caughley LM, et al. Interobserver variation in the reporting of cervical colposcopic biopsy specimens: comparison of grading systems. J Clin Pathol 1996;49:833-35. (Pubitemid 26338564)
20. Kruse AJ, Baak JPA, Janssen EA, et al. Low and high risk CIN1 and 2 lesions: prospective value of grade, HPV and Ki-67 immunoquantitative variables. J Pathol 2003;199:462-70.